Recommendations for defining the preclinical stages of AD are designed to help improve early and accurate clinical diagnoses for potential therapeutic intervention, and as such these efforts require recognition of amyloid and tau pathology, as well as synaptic loss as substrates for the clinical manifestations of AD [144]. Here, MAPT is linked to amyloidosis.